However, pterostilbene plus osimertinib reversed osimertinib-induced phosphorylation of STAT3, Yes-associated protein 1 (YAP1), and CUB domain-containing protein-1 (CDCP1), abrogating the resistance pathways activated by single osimertinib treatment in EGFR-mutated NSCLC [48]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.